8 results on '"Lake, Richard A."'
Search Results
2. Advances in Malignant Mesothelioma.
- Author
-
Robinson, Bruce W.S. and Lake, Richard A.
- Subjects
- *
MESOTHELIOMA , *TUMORS , *CANCER , *PROGNOSIS , *DIAGNOSIS , *DISEASES , *CLINICAL medicine , *ASBESTOS - Abstract
Reviews the key advances in the understanding, diagnosis, and management of malignant mesothelioma that have occurred in the past 5 to 10 years. Description of mesothelioma and who it primarily affects; Symptoms and diagnosis of the disease; Most common physical signs of the disease; How asbestos is the principal carcinogen associated with malignant mesothelioma; Growth of mesothelioma cells in the body; Importance of accurate and rapid diagnosis for therapeutic and medicolegal reasons; Description of treatment options.
- Published
- 2005
- Full Text
- View/download PDF
3. Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model.
- Author
-
Fisher, Scott A., Peddle-McIntyre, Carolyn J., Burton, Kimberley, Newton, Robert U., Marcq, Elly, Lake, Richard A., and Nowak, Anna K.
- Subjects
- *
EXERCISE , *CARCINOGENS , *POPULATION , *ASBESTOS , *TUMORS , *CANCER , *TREADMILL exercise , *MUSCLE growth - Abstract
Objective: There is substantial evidence that exercise can safely reduce the risk of cancer and improve survival in different human cancer populations. Long latency periods associated with carcinogen–induced cancers like asbestos induced mesothelioma provide an opportunity to implement exercise as an intervention to delay or prevent disease development. However, there are limited studies investigating the ability of exercise to prevent or delay cancer, and exercise as a preventive strategy has never been assessed in models with a known carcinogen. We investigated the potential of voluntary exercise (VE) to delay development of asbestos related disease (ARD) in our well-characterised, asbestos induced MexTAg model of mesothelioma. Results: Asbestos exposed MexTAg mice were given continuous or delayed access to VE and ARD assessed over time. We found that the addition of VE did not affect ARD development in asbestos exposed MexTAg mice. However, non–asbestos exposed, aged matched control mice participated in significantly more VE behaviours, suggesting subclinical development of ARD after asbestos exposure had a greater impact on VE participation than age alone. These data highlight the importance of model choice and the potential limitation that some pre–clinical studies may not accurately represent the clinical paradigm, particularly in the context of prevention studies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment.
- Author
-
Aston, Wayne J., Hope, Danika E., Cook, Alistair M., Boon, Louis, Dick, Ian, Nowak, Anna K., Lake, Richard A., and Lesterhuis, W. Joost
- Subjects
- *
LYMPHOCYTES , *B cells , *KILLER cells , *T cells , *DEXAMETHASONE - Abstract
Dexamethasone is a synthetic glucocorticoid commonly used for the prevention and management of side effects in cancer patients undergoing chemotherapy. While it is effective as an anti-emetic and in preventing hypersensitivity reactions, dexamethasone depletes peripheral blood lymphocytes and impacts immune responses. The effect of dexamethasone on the number and quality of tumour-infiltrating leukocytes has not been reported. To address this, we calibrated the dose in two different strains of mice to achieve the same extent of peripheral blood lymphocyte depletion observed in patients with cancer. Doses that caused analogous depletion of T and B lymphocytes and NK cells from the peripheral blood, elicited no change in these populations within the tumour. The expression of immune checkpoint molecules PD-1, OX40, GITR and TIM3 on tumour-infiltrating lymphocytes was not altered. We found that dexamethasone had a small but significant deleterious impact on weakly efficacious chemoimmunotherapy but had no effect when the protocol was highly efficacious. Based on these results, we predict that dexamethasone will have a modest negative influence on the overall effectiveness of chemoimmunotherapy treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.
- Author
-
Aston, Wayne J., Hope, Danika E., Nowak, Anna K., Robinson, Bruce W., Lake, Richard A., and Lesterhuis, W. Joost
- Subjects
- *
CANCER chemotherapy , *ANTINEOPLASTIC agents , *DRUG dosage , *DEXAMETHASONE , *LABORATORY mice , *ANIMAL experimentation , *ANIMALS , *BIOLOGICAL models , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *ETOPOSIDE , *MICE , *TUMORS - Abstract
Background: Cytotoxic chemotherapeutics form the cornerstone of systemic treatment of many cancers. Patients are dosed at maximum tolerated dose (MTD), which is carefully determined in phase I studies. In contrast, in murine studies, dosages are often based on customary practice or small pilot studies, which often are not well documented. Consequently, research groups need to replicate experiments, resulting in an excess use of animals and highly variable dosages across the literature. In addition, while patients often receive supportive treatments in order to allow dose escalation, mice do not. These issues could affect experimental results and hence clinical translation.Methods: To address this, we determined the single-dose MTD in BALB/c and C57BL/6 mice for a range of chemotherapeutics covering the canonical classes, with clinical score and weight as endpoints.Results: We found that there was some variation in MTDs between strains and the tolerability of repeated cycles of chemotherapy at MTD was drug-dependent. We also demonstrate that dexamethasone reduces chemotherapy-induced weight loss in mice.Conclusion: These data form a resource for future studies using chemotherapy in mice, increasing comparability between studies, reducing the number of mice needed for dose optimisation experiments and potentially improving translation to the clinic. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
6. The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer.
- Author
-
Khong, Andrea, Nelson, Delia J., Nowak, Anna K., Lake, Richard A., and Robinson, Bruce W.S.
- Subjects
- *
CANCER treatment , *ANTINEOPLASTIC agents , *IMMUNE response , *DENDRITIC cells , *CLINICAL trials - Abstract
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to its action on both immune and tumor cells. It has the ability to 'precondition' dendritic cells, allowing them to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an ideal therapy for combination with traditional cancer treatments (i.e., chemotherapy, surgery) in order to elicit immune-mediated anti-tumor effects. This review summarizes the mechanisms of action of agonistic anti-CD40, the use of mouse models to investigate its effects and combinations with other therapies in vivo, and current clinical trials combining humanized anti-CD40 antibody with chemotherapy and/or other immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
- Author
-
Bott, Matthew, Brevet, Marie, Taylor, Barry S., Shimizu, Shigeki, Ito, Tatsuo, Lu Wang, Creaney, Jenette, Lake, Richard A., Zakowski, Maureen F., Reva, Boris, Sander, Chris, Delsite, Robert, Powell, Simon, Qin Zhou, Shen, Ronglai, Olshen, Adam, Rusch, Valerie, and Ladanyi, Marc
- Subjects
- *
MESOTHELIOMA , *CANCER , *GENETIC mutation , *GENES , *HISTONES - Abstract
Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 inactivation, but other highly recurrent mutations have not been described. To identify additional driver genes, we used an integrated genomic analysis of 53 MPM tumor samples to guide a focused sequencing effort that uncovered somatic inactivating mutations in BAP1 in 23% of MPMs. The BAP1 nuclear deubiquitinase is known to target histones (together with ASXL1 as a Polycomb repressor subunit) and the HCF1 transcriptional co-factor, and we show that BAP1 knockdown in MPM cell lines affects E2F and Polycomb target genes. These findings implicate transcriptional deregulation in the pathogenesis of MPM. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
8. Combination immune checkpoint blockade as an effective therapy for mesothelioma.
- Author
-
Solin, Jessica N., Fear, Vanessa S., Tilsed, Caitlin, Chee, Jonathan, Forbes, Catherine A., Casey, Thomas, Joost Lesterhuis, W., Dick, Ian M., Fisher, Scott A., Nowak, Anna K, Robinson, Bruce W., Lake, Richard A., and Lansley, Sally M.
- Subjects
- *
MESOTHELIOMA , *CANCER , *PROGNOSIS , *MELANOMA , *IMMUNOTHERAPY - Abstract
Mesothelioma is an aggressive asbestos induced cancer with extremely poor prognosis and limited treatment options. Immune checkpoint blockade (ICPB) has demonstrated effective therapy in melanoma and is now being applied to other cancers, including mesothelioma. However, the efficacy of ICPB and which immune checkpoint combinations constitute the best therapeutic option for mesothelioma have yet to be fully elucidated. Here, we used our well characterised mesothelioma tumour model to investigate the efficacy of different ICBP treatments to generate effective therapy for mesothelioma. We show that tumour resident regulatory T cell co-express high levels of CTLA-4, OX40 and GITR relative to T effector subsets and that these receptors are co-expressed on a large proportion of cells. Targeting any of CTLA-4, OX40 or GITR individually generated effective responses against mesothelioma. Furthermore, the combination of αCTLA-4 and αOX40 was synergistic, with an increase in complete tumour regressions from 20% to 80%. Other combinations did not synergise to enhance treatment outcomes. Finally, an early pattern in T cell response was predictive of response, with activation status and ICP receptor expression profile of T effector cells harvested from tumour and dLN correlating with response to immunotherapy. Taken together, these data demonstrate that combination ICPB can work synergistically to induce strong, durable immunity against mesothelioma in an animal model. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.